EUVIMEDEUVIMED entdecken
Open Access

Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma

Minjun Lee, Sang Hoon Joo, Yung Hyun Choi, Goo Yoon, Jin Woo Park, Jung-Hyun Shim

Journal of Microbiology and Biotechnology · 17.04.2026 · 36

DOI: 10.4014/jmb.2603.03024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, online erschienen am 17.04.2026. Verfasst von Minjun Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Kor…. Hauptthemen laut MEDLINE: Lignans, Cyclooctanes, Polycyclic Compounds, Reactive Oxygen Species. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea, Jeollanamdo RISE center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LignansCyclooctanesPolycyclic CompoundsReactive Oxygen SpeciesEsophageal Neoplasmsp38 Mitogen-Activated Protein KinasesEsophageal Squamous Cell CarcinomaMAP Kinase Signaling SystemCarcinoma, Squamous CellAntineoplastic AgentsHumansCell Line, TumorApoptosisCell SurvivalMembrane Potential, MitochondrialCell Cycle

Stichwörter der Autor:innen

ApoptosisEsophageal squamous cell carcinomaJNKReactive oxygen speciesSchisandrin Ap38

Substanzen

LignansCyclooctanesPolycyclic CompoundsReactive Oxygen Speciesp38 Mitogen-Activated Protein Kinasesschizandrin AAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Korea.
  • College of Pharmacy, Daegu Catholic University, Gyeongsan 38430, Republic of Korea.
  • Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan 47227, Republic of Korea.
  • Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Korea.
  • The China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan 450008, P.R. China.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT, South Korea
  • Jeollanamdo RISE center
  • Ministry of Education
  • Jeollanamdo, Republic of Korea

Zitieren

APA

Lee, M., Joo, S. H., Choi, Y. H., Yoon, G., Park, J. W., & Shim, J. H. (2026). Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma. Journal of Microbiology and Biotechnology, 36. https://doi.org/10.4014/jmb.2603.03024

Vancouver

Lee M, Joo SH, Choi YH, Yoon G, Park JW, Shim JH. Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma. Journal of Microbiology and Biotechnology. 2026;36. doi:10.4014/jmb.2603.03024

BibTeX
@article{Lee2026,
  author = {Lee, Minjun and Joo, Sang Hoon and Choi, Yung Hyun and Yoon, Goo and Park, Jin Woo and Shim, Jung-Hyun},
  title = {Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma},
  journal = {Journal of Microbiology and Biotechnology},
  year = {2026},
  volume = {36},
  doi = {10.4014/jmb.2603.03024}
}
Kostenlos starten →